After holding the hands of hundreds of children suffering from congenital heart disease, the founder of our technology felt there had to be a better way to provide care to children without having to rely on the highly restrictive MRI. Moreover, she still wanted to provide doctors with complete and full information that they need to monitor the heart state and make a confident diagnosis. It was this immediate need for change and compassion that eventually led to the idea of the VMS and the creation of Ventripoint.


Ventripoint Diagnostics Ltd. (TSXV:VPT, OTCQB:VPTDF) is dedicated to developing quality, smart tools that help solve the immediate needs of our healthcare clinicians,  and most importantly improves the clinical experience for our youngest to oldest patient.   


Innovation starts with big hearts.

We strongly believe our greatest medical achievements rested upon human compassion and dedication.  Thus, we encourage our team to draw upon the heartfelt dedication that drove our founder to find a more accessible approach to monitoring a pediatric patient's heart as a springboard to all  product development.   


We design with the patient and the user in mind.

​When designing our products, we believe that we must always come up with design solutions that both improve the patient's clinical experience and empower the clinician.  Further to this thinking, we think that we  should not lose sight of the fact that we strongly believe in doing our part to promote a strong universal healthcare system. We owe it to our dedicated and caring healthcare providers to develop cost effective medical devices that can reach clinics, and support  the most vulnerable and underserviced populations.


Quality is not about checking the boxes.

We believe in the highest degree of quality for every product we design and develop. We have placed great emphasis on creating and fostering a culture focused on quality.   


We rise together and fall together. 


We believe that our success is a culmination of every team member's success and we each share in all failures.  Our failures make us as strong a team as our successes.  

In keeping with this thinking, we aim to provide our team members with all the opportunities to grow, learn and be inspired.  We also encourage a balance between work and life.  We work hard, but have some fun along the way.  



Dr. George Adams - Chairman of the Board; Member of Nominating & Corporate Governance Committee and Audit Committee.

Dr. Adams is a scientist, a serial entrepreneur and a financier. His previous position was CEO of Amorfix Life Sciences (TSX:AMF) from 2005-2010. He was Chairman of Sernova Corp (TSXV:SVA) and President and CEO of the UT Innovations Foundation from 1999 until 2004. Prior to this, he held research and executive positions with Boston Scientific Inc, Pfizer Inc, Corvita Canada Inc., University of Ottawa and Canadian Red Cross, Blood Transfusion Service. He has been instrumental in founding over 30 companies who have raised $100 million and has been a Director of 10 venture capital funds and 10 start-up companies. .Dr. Adams was awarded a World Economic Foundation Technology Pioneer for 2007 and TBI Company of the year in 2009. Dr Adams has 124 scientific publications and is a reviewer for major scientific journals, federal granting agencies and Centres of Excellence.

Robert Hodgkinson - Director

Mr. Hodgkinson has over 40 years of experience in public and venture capital markets.  He has raised $150,000+ of capital for numerous companies and is an experienced corporate director, senior executive and adviser.  He has been instrumental in successful merger and acquisitions in oil and gas transactions totaling $500M+ and has acted as a principal and agent in corporate structuring/restructuring.



Peter Weichler - Board Secretary 

Mr. Wiechler is presently a partner in the firm Candela Capital based in Calgary. His background in finance includes commercial banking, stock brokerage, investor relations and investment banking with national Canadian firms. He is well versed in capital raising for emerging and entrepreneurial public companies.